RT Journal Article SR Electronic T1 Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 2549 OP 2559 DO 10.21873/invivo.12072 VO 34 IS 5 A1 HIROKI NISHIKAWA A1 KAZUNORI YOH A1 HIRAYUKI ENOMOTO A1 YOSHINORI IWATA A1 YOSHIYUKI SAKAI A1 KYOHEI KISHINO A1 YOSHIHIRO SHIMONO A1 NAOTO IKEDA A1 TOMOYUKI TAKASHIMA A1 NOBUHIRO AIZAWA A1 RYO TAKATA A1 KUNIHIRO HASEGAWA A1 TAKASHI KORIYAMA A1 YUKIHISA YURI A1 TAKASHI NISHIMURA A1 SHUHEI NISHIGUCHI A1 HIROKO IIJIMA YR 2020 UL http://iv.iiarjournals.org/content/34/5/2549.abstract AB Aim: To elucidate the common and different points between sarcopenia and frailty in chronic liver damage (CLD). Patients and Methods: Patients with both grip strength decline and skeletal muscle index decline were regarded as sarcopenia. Frailty was defined as a syndrome in which 3 or more of the following criteria were met: i) exhaustion, ii) body weight loss, iii) slow walking speed, iv) muscle weakness, and v) low physical activity. Results: Sarcopenia and frailty were identified in 52 patients (15.2%) and 46 (13.5%), respectively. The prevalence of sarcopenia and frailty was well stratified according to age and the liver cirrhosis (LC) status. In the multivariate analysis, we identified significant factors for sarcopenia: i) age, ii) LC, iii) body mass index and iv) extracellular water (ECW) to total body water (TBW) ratio, while only the ECW to TBW ratio was significant for frailty. Conclusion: Sarcopenia and frailty in CLD should be separately evaluated.